Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2021 / N 3

Вторичная профилактика ишемического инсульта в эпоху COVID-19
А.Н. Боголепова, С.В. Заболотная

References

1. Federal State Statistics Service (Rosstat). Healthcare in Russia. 2019. Statistical collection. Moscow: Rosstat; 2019. 170 p.
2. Kauw F, Greving JP, Takx RAP, de Jong HWAM, Schonewille WJ, Vos JA, Wermer MJH, van Walderveen MAA, Kappelle LJ, Velthuis BK, Dankbaar JW; Dutch acute stroke study (DUST) investigators. Prediction of long-term recurrent ischemic stroke: the added value of non-contrast CT, CT perfusion, and CT angiography. Neuroradiology 2021 Apr;63(4):483-90.
3. Kolmos M, Christoffersen L, Kruuse C. Recurrent ischemic stroke – a systematic review and meta-analysis. Journal of Stroke and Cerebrovascular Diseases 2021 Aug;30(8):105935.
4. Maksimova MYu. Current opportunities for secondary prevention of atherothrombotic stroke. SS Korsakov Journal of Neurology and Psychiatry 2021;121(8):97-105 (In Russian).
5. Tairova RT. Features of pharmacological action and use of dipyridamole for secondary prevention of ischemic stroke. Consilium Medicum 2017;19(2.3. Neurology and Rheumatology):15-8 (In Russian).
6. Solovyeva EYu, Dzhutova ED, Tyutyumova EA. Antiplatelet therapy as an element of primary and secondary prevention of ischemic stroke. Medical Council 2016;8:24-33 (In Russian).
7. Rodríguez-Yáñez M, Castillo J. Role of inflammatory markers in brain ischemia. Current Opinion in Neurology 2008 Jun;21(3):353-7.
8. Zabolotnaya SV, Bogolepova AN, Tairova RT. COVID-19-associated stroke. SS Korsakov Journal of Neurology and Psychiatry 2021;121(8-2):5-10 (In Russian).
9. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine 2020 Apr;382(18):1708-20.
10. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020 Mar;323(11):1061-9.
11. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical Infectious Diseases 2020 Jul;71(15):762-8.
12. Nannoni S, de Groot R, Bell S, Markus HS. Stroke in COVID-19: a systematic review and meta-analysis. International Journal of Stroke 2021 Feb;16(2):137-49.
13. Li Y, Li M, Wang M, Zhou Y, Chang J, Xian Y, Wang D, Mao L, Jin H, Hu B. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke and Vascular Neurology 2020 Sep;5(3):279-84.
14. Roy D, Ghosh R, Dubey S, Dubey MJ, Benito-León J, Kanti Ray B. Neurological and neuropsychiatric impacts of COVID-19 pandemic. The Canadian Journal of Neurological Sciences 2021 Jan;48(1):9-24.
15. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, De Leacy RA, Shigematsu T, Ladner TR, Yaeger KA, Skliut M, Weinberger J, Dangayach NS, Bederson JB, Tuhrim S, Fifi JT. Large-vessel stroke as a presenting feature of Covid-19 in the young. The New England Journal of Medicine 2020;382(20):e60.
16. Martynov MYu, Bogolepova AN, Yasamanova AN. Endothelial dysfunction in COVID-19 and cognitive impairment. SS Korsakov Journal of Neurology and Psychiatry 2021;121(6):93-9 (In Russian).
17. Nägele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: current findings and therapeutic implications. Atherosclerosis 2020;314:58-62.
18. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Research Square 2021 Jan;2021.01.27.21250617.
19. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, Kucher N, Studt JD, Sacco C, Bertuzzi A, Sandri MT, Barco S; Humanitas COVID-19 Task Force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thrombosis Research 2020;191:9-14.
20. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji H, Clere-Jehl R, Schenck M, Fagot Gandet F, Fafi-Kremer S, Castelain V, Schneider F, Grunebaum L, Anglés-Cano E, Sattler L, Mertes PM, Meziani F; CRICS TRIGGERSEP Group. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Medicine 2020 Jun;46(6):1089-98.
21. Goldberg MF, Goldberg MF, Cerejo R, Tayal AH. Cerebrovascular disease in COVID-19. AJNR. American Journal of Neuroradiology 2020;41(7):1170-2.
22. Temporary methodological recommendations. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Version 13 (14.10.2021). Available from: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf Accessed 2021 Oct 17. (In Russian).
23. Fara MG, Stein LK, Skliut M, Morgello S, Fifi JT, Dhamoon MS. Macrothrombosis and stroke in patients with mild Covid-19 infection. Journal of Thrombosis and Haemostasis 2020 Aug;18(8):2031-3.
24. Mohamud AY, Griffith B, Rehman M, Miller D, Chebl A, Patel SC, Howell B, Kole M, Marin H. Intraluminal carotid artery thrombus in COVID-19: another danger of cytokine storm? AJNR. American Journal of Neuroradiology 2020 Sep;41(9):1677-82.
25. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID-19. Journal of Cardiovascular Electrophysiology 2020;31(5):1003-8.
26. Morassi M, Bagatto D, Cobelli M, D’Agostini S, Gigli GL, Bnà C, Vogrig A. Stroke in patients with SARS-CoV-2 infection: case series. Journal of Neurology 2020;267(8):2185-92.
27. Kim AS. Medical management for secondary stroke prevention. Continuum: Lifelong Learning in Neurology 2020 Apr;26(2):435-56.
28. Vahabizad F, Sharifian Dorche M, Mohammadi P, Khatibi K, Mowla A. COVID-19-related acute ischemic stroke in young adults: what is the optimal antithrombotic regimen for secondary prevention? Journal of Neurology Research 2020 Oct;10(5):203-6.
29. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 Jan;324(7329):71-86.
30. Bath PM, Wardlaw JM. Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. International Journal of Stroke 2015 Jun;10(4):469-78.
31. Lana D, Melani A, Pugliese AM, Cipriani S, Nosi D, Pedata F, Giovannini MG. The neuron-astrocyte-microglia triad in a rat model of chronic cerebral hypoperfusion: protective effect of dipyridamole. Frontiers in Aging Neuroscience 2014 Nov;6:322.
32. Venkatesh PK, Pattillo CB, Branch B, Hood J, Thoma S, Illum S, Pardue S, Teng X, Patel RP, Kevil CG. Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway. Cardiovascular Research 2010 Mar;85(4):661-70.
33. Heistad DD, Marcus ML, Gourley JK, Busija DW. Effect of adenosine and dipyridamole on cerebral blood flow. The American Journal of Physiology 1981 May;240(5):H775-80.
34. Tanashyan MM, Domashenko MA. Dipyridamole in complex therapy of chronic cerebrovascular diseases. Nervous Diseases 2012;3:27-30 (In Russian).
35. Cardiovascular prevention 2017. National guidelines. Russian Journal of Cardiology 2018;23(6):7-122 (In Russian).
36. Al-Bahrani A, Taha S, Shaath H, Bakhiet M. TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. Current Neurovascular Research 2007 Feb;4(1):31-7.
37. Kareva EN. Features of pharmacological action and use of dipyridamole in prevention and treatment of viral infections. Consilium Medicum 2016;18(12):80-7 (In Russian).
38. Jefferson TO, Tyrrel D. Antivirals for the common cold. The Cochrane Database of Systematic Reviews 2001;(3):CD002743.
39. Liu X, Li Z, Liu S, Chen Z, Sun J, Zhao Z, Huang Y, Zhang Q, Wang J, Shi Y, Xu Y, Xian H, Fang R, Bai F, Ou C, Xiong B, Lew AM, Cui J, Huang H, Zhao J, Hong X, Zhang Y, Zhou F, Luo H. Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction. medRxiv 2020.02.27.20027557.
40. McFadyen JD, Stevens H, Peter K. The emerging threat of (micro)thrombosis in COVID-19 and its therapeutic implications. Circulation Research 2020 Jul;127(4):571-87.
41. Liu X, Li Z, Liu S, Sun J, Chen Z, Jiang M, Zhang Q, Wei Y, Wang X, Huang YY, Shi Y, Xu Y, Xian H, Bai F, Ou C, Xiong B, Lew AM, Cui J, Fang R, Huang H, Zhao J, Hong X, Zhang Y, Zhou F, Luo HB. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharmaceutica Sinica. B 2020 Jul;10(7):1205-15.
42. Kalayoglu Besisik S, Ozbalak M, Tor YB, Alibeyoglu A, Kose M, Şenkal N, Cagatay A, Erelel M, Gul A, Esen F, Umman S, Isoglu Alkoclar U, Tukek T. Dipyridamole added to anticoagulant prophylaxis: decline in poor outcome of clinically severe ill COVID-2019 patients [abstract]. Research and Practice in Thrombosis and Haemostasis 2020;4(Suppl 1):PB/CO01. Available from: https://abstracts.isth.org/abstract/dipyridamole-added-to-anticoagulant-prophylaxis-decline-in-poor-outcome-of-clinically-severe-ill-covid-2019-patients/ Accessed 2021 Oct 17.
43. Putilina MV, Grishin DV. SARS-CoV-2 (COVID-19) as a predictor of neuroinflammation and neurodegeneration: potential therapy strategies. SS Korsakov Journal of Neurology and Psychiatry 2020;120(8-2):58-64 (In Russian).
44. Aliter KF, Al-Horani RA. Potential therapeutic benefits of dipyridamole in COVID-19 patients. Current Pharmaceutical Design 2021;27(6):866-75.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]